ARA-290 / cibinetide dosing schedule
> Updated:
Calculate the ARA-290 dose
The calculator is already set up for ARA-290 — adjust the dose or diluent volume for your vial.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Tolerance assessment | 1–2 mg subcutaneously, once daily | Starting dose |
| Main course (28 days) | 4 mg subcutaneously, once daily | Main studied dose |
| Upper studied bound | 8 mg subcutaneously, once daily | Maximum in this schedule |
Practical dosing and effect details
In a study by Brines and colleagues (Molecular Medicine, 2015), patients with type 2 diabetes self-administered 4 mg of subcutaneous ARA-290 (cibinetide) daily for 28 days, followed by an additional month of observation without treatment. Over that period, HbA1c fell significantly (p=0.002) and PainDetect neuropathic symptom scores improved (p=0.03); the cholesterol-to-HDL ratio (p=0.039) and triglycerides (p=0.043) also declined. The effect persisted across the full 56-day observation, including the month without dosing, pointing to a slow-building effect rather than a short-lived response to a single injection. The 4 mg daily dose used in this study matches the main regimen in the table on this page; the higher and lower figures there mark the range studied in the same trial. This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.ARA-29010 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =ARA-2905 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 4 mg dose:4 mg = 0.8 ml= 80 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
ARA-290: reference regimens
ARA-290 (cibinetide) was administered subcutaneously (SubQ) once daily in studies.
ARA-290 dosing (cibinetide) in the studies is always described as one subcutaneous injection per day rather than a dose split across multiple administrations, unlike some other peptides on this site.
More scientific background in the ARA-290 monograph
Notes and safety
- • ARA-290 is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
ARA-290